Onyx Pharmaceuticals ( ONXX) said Wednesday that its cancer drug Nexavar extended progression-free survival in a mid-stage study of women with advanced breast cancer.

The announcement helped push Onyx shares up 29% to $37 in pre-market trading.

Nexavar, a pill, is currently marketed as a treatment for kidney and liver cancers. Onyx and its partner, the German drug firm Bayer, have been testing Nexavar in other types of cancer as well.

The phase II study announced Wednesday evaluated treatment with Nexavar and the oral chemotherapy drug Xeloda, marketed by Roche, compared to Xeloda plus placebo.

Women with advanced Her-2 negative breast cancer treated with the Nexavar-Xeloda combination demonstrated a lengthening of time before their cancer grew compared to woman treated with Xeloda alone.

Onyx said the results were statistically significant although details about the study were being withheld so that they could be presented later at a medical conference.

"Based on these encouraging data, Onyx and Bayer are evaluating various strategies for Nexavar in breast cancer," said Dr. Todd Yancey, vice president of clinical development at Onyx.

Onyx and Bayer are currently conducting other phase II studies of Nexavar in breast cancer.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Micron Shares Soar; Chipmaker Is 'Managing for Profitability' Now, Says Analyst

Micron Shares Soar; Chipmaker Is 'Managing for Profitability' Now, Says Analyst

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline